Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) insider Noah Goodman sold 5,000 shares of the firm’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $114.00, for a total value of $570,000.00. Following the completion of the transaction, the insider owned 50,195 shares of the company’s stock, valued at approximately $5,722,230. This represents a 9.06% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Noah Goodman also recently made the following trade(s):
- On Monday, June 22nd, Noah Goodman sold 2,500 shares of Kymera Therapeutics stock. The stock was sold at an average price of $99.00, for a total transaction of $247,500.00.
- On Tuesday, April 14th, Noah Goodman sold 1,347 shares of Kymera Therapeutics stock. The stock was sold at an average price of $90.00, for a total transaction of $121,230.00.
- On Friday, April 10th, Noah Goodman sold 2,000 shares of Kymera Therapeutics stock. The shares were sold at an average price of $87.35, for a total transaction of $174,700.00.
- On Thursday, April 9th, Noah Goodman sold 8,264 shares of Kymera Therapeutics stock. The shares were sold at an average price of $87.50, for a total transaction of $723,100.00.
Kymera Therapeutics Price Performance
KYMR traded up $16.59 during midday trading on Thursday, reaching $116.46. 3,915,007 shares of the company’s stock were exchanged, compared to its average volume of 726,535. The stock has a market capitalization of $9.58 billion, a PE ratio of -32.62 and a beta of 2.02. The business’s 50-day moving average price is $83.90 and its 200 day moving average price is $81.77. Kymera Therapeutics, Inc. has a 1-year low of $36.65 and a 1-year high of $130.05.
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of KYMR. Smartleaf Asset Management LLC lifted its stake in shares of Kymera Therapeutics by 382.0% during the 4th quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock worth $42,000 after purchasing an additional 424 shares during the period. Larson Financial Group LLC grew its position in shares of Kymera Therapeutics by 81.5% in the third quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock valued at $44,000 after purchasing an additional 349 shares during the period. Osaic Holdings Inc. increased its stake in Kymera Therapeutics by 18,050.0% in the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock valued at $48,000 after purchasing an additional 1,083 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in Kymera Therapeutics in the fourth quarter valued at $63,000. Finally, Raymond James Financial Inc. purchased a new position in Kymera Therapeutics during the second quarter worth about $73,000.
Wall Street Analyst Weigh In
A number of equities research analysts have commented on KYMR shares. Morgan Stanley reissued an “overweight” rating and set a $119.00 price target on shares of Kymera Therapeutics in a research report on Thursday, April 30th. Wall Street Zen upgraded Kymera Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kymera Therapeutics in a research note on Tuesday, April 21st. Stephens boosted their target price on shares of Kymera Therapeutics from $95.00 to $100.00 and gave the company an “overweight” rating in a research note on Monday, March 2nd. Finally, Brookline Capital Markets restated a “buy” rating on shares of Kymera Therapeutics in a report on Monday, June 8th. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Kymera Therapeutics has an average rating of “Moderate Buy” and an average price target of $117.14.
Get Our Latest Stock Report on Kymera Therapeutics
More Kymera Therapeutics News
Here are the key news stories impacting Kymera Therapeutics this week:
- Positive Sentiment: Kymera completed enrollment in its Phase 2b BROADEN2 trial for KT-621 in moderate to severe atopic dermatitis well ahead of expectations, improving confidence in the program’s development timeline. Article Title
- Positive Sentiment: The company said KT-621 Phase 3 trials in atopic dermatitis are planned to start by mid-2027, signaling continued pipeline momentum. Article Title
- Positive Sentiment: BTIG reaffirmed its Buy rating on Kymera and maintained a $134 price target, reinforcing bullish analyst sentiment. Article Title
- Neutral Sentiment: The stock was also featured among midday market movers and in reports noting a new 1-year high, reflecting strong trading momentum. Article Title
- Neutral Sentiment: Kymera appointed Felix J. Baker, Ph.D. as chairman of the board, a governance update with limited immediate impact on fundamentals. Article Title
About Kymera Therapeutics
Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.
The company’s pipeline emphasizes immunology and oncology.
Featured Articles
- Five stocks we like better than Kymera Therapeutics
- MDA Space Targets US Defense Market With $620M Acquisition
- Carnival’s Second Quarter: Is the Stock Still Complicated?
- Domino’s Stock Slides to 52-Week Low as Investors Digest CEO Change
- Microsoft Solves AI’s Biggest Bottleneck With Chevron Deal
Receive News & Ratings for Kymera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kymera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
